Reduced expression of peroxisome proliferator-activated receptor-α may have an important role in the development of non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 7, 2004, Pages 799-804

  Jong, Eun Yeon ^a   Kyung, Mook Choi ^a   Sei, Hyun Baik ^a   Kyoung, Oh Kim ^a   Hyoung, Joon Lim ^a   Ki, Ho Park ^a   Jin, Yong Kim ^a   Park, Jong Jae ^a   Jae, Seon Kim ^a   Bak, Young Tae ^a   Kwan, Soo Byun ^a   Chang, Hong Lee ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Acyl CoA oxidase; Beta oxidation; Fatty acid; Non alcoholic fatty liver disease; Peroxisome proliferator activated receptor

Indexed keywords

ACYL COENZYME A OXIDASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; HISTOPATHOLOGY; INFLAMMATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEATOSIS; WESTERN BLOTTING;

EID: 3242795074     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03349.x     Document Type: Article

References (21)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
3. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
4. Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000; 20: 191-9.
5. Lee SS, Pineau T, Drago J et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 1995; 15: 3012-22.
6. Aoyama T, Peters JM, Iritani N et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998; 273: 5678-84.
7. Fan CY, Pan J, Chu R et al. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J. Biol. Chem. 1996; 271: 24698-710.
8. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 1999; 96: 7473-8.
9. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 1998; 273: 29577-85.
10. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
11. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
12. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
13. Sheng B, Moran TH. Actions of CCK in the controls of food intake and body weight: lessons from the CCK-A receptor deficient OLETF rat. Neuropeptides 2002; 36: 171-81.
14. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am. J. Physiol. 1998; 274: R618-25.
15. Schwartz GJ, Whitney A, Skoglund C, Castonguay TW, Moran TH. Decreased responsiveness to dietary fat in Otsuka Long-Evans Tokushima fatty rats lacking CCK-A receptors. Am. J. Physiol. 1999; 277: R1144-51.
16. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acylCoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem. 1998; 273: 15639-45.
17. Hashimoto T, Fujita T, Usuda N et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J. Biol. Chem. 1999; 274: 19 228-36.
18. Mannaerts GP, Debeer LJ, Thomas J, De Schepper PJ. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. J. Biol. Chem. 1979; 254: 4585-95.
19. Fan CY, Pan J, Chu R et al. Targeted disruption of the peroxisomal fatty acyl-CoA oxidase gene: generation of a mouse model of pseudoneonatal adrenoleukodystrophy. Ann. N.Y. Acad. Sci. 1996; 804: 530-41.
20. Ide T, Shimano H, Yoshikawa T et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol. Endocrinol. 2003; 17: 1255-67.
21. Kliewer SA, Sundseth SS, Jones SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl Acad. Sci. USA 1997; 94: 4318-23.